Copeptin Blood Content as a Diagnostic Marker of Chronic Kidney Disease

Area of Science:

• Nephrology
• Cardiology
• Biomarker Discovery

Background:

• Plasma copeptin concentrations increase with advancing chronic kidney disease (CKD).
• Copeptin's utility as a biomarker in CKD, with or without heart failure, requires further investigation.

Purpose of the Study:

• To evaluate plasma copeptin levels as a potential biomarker for CKD progression.
• To assess copeptin's role in patients with CKD and coexisting heart failure.

Main Methods:

• Seventy-six patients were stratified into control and CKD groups (stages 3a, 3b, 4, 5), including one with CKD stage 3b and heart failure.
• Plasma levels of copeptin, creatinine, urea, cystatin C, CRP, NT-proBNP, and blood pH were measured.
• Ratio analysis (copeptin/creatinine, copeptin/cystatin C, copeptin/eGFR, copeptin×NT-proBNP, copeptin×NT-proBNP/creatinine) was performed.

Main Results:

• Plasma copeptin, creatinine, urea, CRP, cystatin C, and NT-proBNP levels significantly increased with CKD progression.
• Heart failure did not substantially elevate copeptin levels in CKD patients.
• Copeptin/eGFR ratio demonstrated enhanced prognostic sensitivity for renal failure in CKD compared to copeptin alone.
• The copeptin×NT-proBNP ratio decreased with CKD progression, while the copeptin×NT-proBNP/creatinine ratio increased, indicating cardiac function decline.

Conclusions:

• Copeptin is a valuable biomarker for CKD progression.
• Copeptin is not a significant indicator of heart failure in the context of CKD.
• Ratios involving copeptin, particularly copeptin/eGFR, improve CKD assessment.
• Changes in copeptin×NT-proBNP and copeptin×NT-proBNP/creatinine ratios effectively reflect cardiac function decline in CKD patients.